Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study
| Title: | Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study |
|---|---|
| Authors: | Baltazar Nunes, James Humphreys, Nathalie Nicolay, Toon Braeye, Izaak Van Evercooren, Christian Holm Hansen, Ida Rask Moustsen-Helms, Chiara Sacco, Massimo Fabiani, Jesús Castilla, Iván Martínez-Baz, Hinta Meijerink, Ausenda Machado, Patricia Soares, Rickard Ljung, Nicklas Pihlström, Anthony Nardone, Sabrina Bacci, Susana Monge |
| Source: | Expert Review of Vaccines, Vol 23, Iss 1, Pp 1085-1090 (2024) |
| Publisher Information: | Taylor & Francis Group, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Internal medicine |
| Subject Terms: | COVID-19, SARS-CoV-2, vaccine effectiveness, hospitalization, cohort design, electronic health records, Internal medicine, RC31-1245 |
| More Details: | Background We aimed to estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalizations and deaths during BA.2.86/JN.1 predominance, among EU/EEA individuals with ≥65-years.Research design and methods We linked electronic health records to create historical cohorts in Belgium, Denmark, Italy, Navarre (Spain), Norway, Portugal and Sweden. We included individuals aged ≥65-years eligible for the autumnal 2023 COVID-19 vaccine. Follow-up started when ≥80% of country-specific sequenced viruses were BA.2.86/JN.1 (4/dec/23 to 08/jan/24) and ended 25 February 2024. At study site level, we estimated the vaccine confounder-adjusted hazard ratio (aHR) of COVID-19 hospitalizations and deaths between individuals with ≥14 days after vaccination versus unvaccinated in autumn 2023, overall, by time since vaccination and age groups. VE was estimated as (1-pooled aHR)x100 with a random-effects model.Results XBB.1.5 VE against COVID-19 hospitalizations was 50% (95%CI: 45 to 55) and 41% (95%CI: 35 to 46) in 65–79-year-olds and in ≥80-year-olds, respectively. VE against COVID19-related-death was 58% (95%CI: 42 to 69) and 48% (95%CI: 38 to 57), respectively, in both age groups. VE estimates against each outcome declined in all age groups over time.Conclusion Monovalent XBB.1.5 vaccine had a moderate protective effect against severe and fatal COVID-19 likely caused by BA.2.86/JN.1 during the 2023/2024 winter, among persons aged ≥65. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 14760584 1744-8395 1476-0584 |
| Relation: | https://doaj.org/toc/1476-0584; https://doaj.org/toc/1744-8395 |
| DOI: | 10.1080/14760584.2024.2428800 |
| Access URL: | https://doaj.org/article/eafb3041a9b34ec5bef9e8604c8a60ba |
| Accession Number: | edsdoj.fb3041a9b34ec5bef9e8604c8a60ba |
| Database: | Directory of Open Access Journals |
| ISSN: | 14760584 17448395 |
|---|---|
| DOI: | 10.1080/14760584.2024.2428800 |
| Published in: | Expert Review of Vaccines |
| Language: | English |